Results 131 to 140 of about 415,967 (312)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Adaptive Estimation of Autoregressive Models with Time-Varying Variances [PDF]

Stable autoregressive models of known finite order are considered with martingale differences errors scaled by an unknown nonparametric time-varying function generating heterogeneity.
Peter C.B. Phillips, Ke-Li Xu
core  

Erratum: Variance estimation for effective coverage measures: A simulation study. [PDF]

J Glob Health, 2021
Leslie H.
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Restricted Maximum Likelihood Estimation of Variance Components for Univariate Animal Models Using Sparse Matrix Techniques and Average Information

, 1995
An algorithm is described to estimate variance components for a univariate animal model using REML. Sparse matrix techniques are employed to calculate those elements of the inverse of the coefficient matrix required for the first derivatives of the ...
JOHNSON, DL, THOMPSON, R
core  

Robust variance-constrained filtering for a class of nonlinear stochastic systems with missing measurements

, 2010
The official published version of the article can be found at the link below.This paper is concerned with the robust filtering problem for a class of nonlinear stochastic systems with missing measurements and parameter uncertainties.
Zidong Wang, Lifeng Ma, Wang, Z, Jun Hu, Hu, J, Bo, S, Yuming Bo, Zhi Guo, Ma, L, Guo, Z   +9 more
core   +1 more source

Variance estimation from integrated likelihoods (VEIL)

Genetics Selection Evolution, 1990
Foulley JL, Gianola D
doaj   +1 more source

A comparison between Bayes estimation and the estimation of the minimal unbiased quadratic Standard of the bi-division variance analysis model in the presence of interaction

Tikrit Journal of Pure Science, 2020
In this study, the variance compounds parameters of the mixed bi-division variance analysis sample are estimated. This estimation is obtained, by Bayes quadratic unbiased estimator. The second way to estimate variance compounds parameters of a suggested
Shaymaa Riyadh Thanoon
doaj  

Bootstrap vs asymptotic variance estimation when using propensity score weighting with continuous and binary outcomes. [PDF]

Stat Med, 2022
Austin PC.
europepmc   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source